Zacks Research Has Positive Outlook of UTHR FY2024 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Zacks Research raised their FY2024 EPS estimates for United Therapeutics in a research note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn $24.45 per share for the year, up from their prior estimate of $23.30. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.93 EPS, Q2 2025 earnings at $6.63 EPS and Q2 2026 earnings at $6.47 EPS.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the prior year, the company posted $5.38 EPS. The firm’s revenue was up 22.9% on a year-over-year basis.

UTHR has been the topic of several other research reports. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Bank of America cut their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Stock Up 1.0 %

NASDAQ:UTHR opened at $364.33 on Thursday. The company’s 50 day moving average is $363.86 and its 200-day moving average is $330.33. The firm has a market cap of $16.27 billion, a price-to-earnings ratio of 16.00, a P/E/G ratio of 1.05 and a beta of 0.56. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $417.82.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. TD Private Client Wealth LLC boosted its position in shares of United Therapeutics by 10.8% in the 3rd quarter. TD Private Client Wealth LLC now owns 3,688 shares of the biotechnology company’s stock worth $1,322,000 after purchasing an additional 358 shares during the last quarter. Toronto Dominion Bank increased its stake in shares of United Therapeutics by 22.6% in the 3rd quarter. Toronto Dominion Bank now owns 5,546 shares of the biotechnology company’s stock valued at $1,987,000 after acquiring an additional 1,021 shares during the last quarter. Chiron Investment Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $391,000. Coldstream Capital Management Inc. boosted its stake in United Therapeutics by 3.8% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,166 shares of the biotechnology company’s stock worth $779,000 after acquiring an additional 79 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. The trade was a 67.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,796 shares of company stock worth $40,936,370 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.